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Prostate cancer (CaP) is the commonest malignancy to affect in men in the UK. Extraprostatic disease 
detection at staging and in the setting of biochemical recurrence (BCR) is essential in determining 
treatment strategy. Conventional imaging including computed tomography (CT) and bone scintigraphy 
(BS) are limited in their ability to detect sites of loco-regional nodal and metastatic bone disease, 
particularly at clinically relevant low prostate specific antigen (PSA) levels. The use of positron 
emission tomography-computed tomography (PET-CT) has helped overcome these deficiencies and is 
leading a paradigm shift in the management of CaP using a wide range of radiopharmaceuticals. Their 
mechanisms of action, utility in both staging and BCR, and comparative strengths and weaknesses will 
be covered in this article. 
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BCR = biochemical recurrence 
BPH = benign prostatic hyperplasia 
BS = bone scintigraphy 
CaP = prostate cancer 
CT = computed tomography 
DCE = dynamic contrast enhanced 
DR = detection rate 
DW = diffusion weighted 
EMA = European Medicines Agency 
FCH = [18F]fluoromethylcholine 
FDA = Food and Drug Administration 
FEC = [18F]fluoroethylcholine 
GS = Gleason Score 
MIP = maximum intensity projection 
mpMRI = multiparametric magnetic resonance imaging 
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PET = positron emission tomography 
p.i = post-injection 
PIRADS = Prostate Imaging Reporting and Data System 
PSA = prostate specific antigen 
PSAdt = PSA doubling time 
PSAvel = PSA velocity 
PSMA = prostate specific membrane antigen 
rhPSMA = radiohybrid PSMA 
RP = radical prostatectomy 
RT = radiotherapy 
SPECT = single photon emission computed tomography 
SUVmax = maximum standardised uptake value 
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INTRODUCTION 
Prostate cancer (CaP) is the commonest cancer in men, with nearly 43,000 cases diagnosed in England 
and Wales in 2017-181. Since the mid-1990s, incidence has risen by over 40%, due to an ageing 
population and increased detection, e.g. prostate specific antigen (PSA) testing, but has been 
accompanied by improved survival, due to earlier detection of low-risk slow growing cancers and more 
effective treatments. However, mortality rates remain static in several age groups, and have overall 
increased by 20% since the 1970s, reflecting ongoing mortality associated with high-risk aggressive 
CaP2. 
 
Extraprostatic disease detection is paramount in deciding the most appropriate treatment strategy. 
Despite the excellence of multiparametric magnetic resonance imaging (mpMRI), which includes 
diffusion weighted (DW) and dynamic contrast enhanced (DCE) imaging, for local staging3, the 
sensitivity of conventional MRI4,5 and computed tomography (CT)5, for loco-regional nodal disease 
detection is limited, due to the inadequacy of size thresholds (8-10mm short axis diameter) to detect 
disease in otherwise normal appearing nodes, whilst bone scintigraphy (BS), the historic mainstay of 
metastatic bone disease assessment, has a diagnostic yield highly dependent on PSA level with poor 
exclusion for metastatic disease especially at low PSA levels6,7. 
 
Imaging research has focused on developing positron emission tomography (PET) 
radiopharmaceuticals that address these deficiencies. This article covers the common PET 
radiopharmaceuticals available for the simultaneous assessment of local, nodal, and distant disease, 
their mechanisms of action, use in both staging and biochemical recurrence (BCR), and comparative 
strengths and weaknesses. The use of 2-deoxy-2[18F]fluoro-D-glucose PET-CT, which is of limited 
benefit in hormone sensitive CaP, but is helping guide evolving therapeutic strategies using molecular 
radiotherapy for advanced aggressive metastatic castrate resistant CaP, is beyond the scope of this 
article but is discussed in detail in a recent review by Siva et al8. 
 
PET RADIOPHARMACEUTICALS 
Radiolabelled choline analogues 
Choline enters cells via cell surface transporters, and is phosphorylated by choline kinase into 
phosphocholine, a precursor of phosphatidylcholine, the major phospholipid component of cell 
membranes9. Radiolabelled choline uptake in CaP cells reflects increased expression of cell surface 
choline transporters10 and upregulation of choline kinase activity11 but not increased cellular 
proliferation or cell membrane synthesis per se11,12. 
 
The major advantages of [11C]choline include minimal urinary excretion, allowing accurate assessment 
of the prostate bed and pelvic nodal basins, and early post-injection (p.i) imaging (5-15 minutes)13 but 
its major drawback is its short half-life (20 minutes), limiting use to institutions with cyclotrons. The 
choline-inspired radiopharmaceuticals, [18F]fluoromethylcholine (FCH) and [18F]fluoroethylcholine 
(FEC), were developed to take advantage of the longer half-life of [18F] (110 minutes), and permit more 
widespread availability. Despite high urinary excretion, and potential to hinder assessment of the 
pelvis, FCH/FEC have a higher positive detection rate (DR) than [11C]choline14, whilst FCH may have a 
higher diagnostic performance than FEC15.  
 
A traditional FEC/FCH imaging protocol comprises early dynamic and delayed (90 minutes p.i) pelvic 
imaging with half body imaging at 60 minutes p.i; the pelvic acquisitions help differentiate pathological 
prostatic uptake from physiological urinary activity and help characterise the nature of pelvic nodes; 
these acquisitions can however be safely omitted without adverse effect on accuracy16. Physiological 
uptake is observed in the salivary glands, liver, kidneys, pancreas, spleen, bone marrow and bowel 
with low-grade uptake frequently observed in reactive nodes in the groins, axillae and chest (Figure 
1). A recommended injected activity of 4 MBq/kg up to 370 MBq results in a maximum effective dose 
of 6.4 mSv17. 
 
[18F]Fluciclovine 
[18F]Fluciclovine or [18F]FACBC, is a radiolabelled synthetic amino acid analogue, initially developed to 
image brain tumours18 whose utility in CaP was incidentally discovered during a study of renal 
carcinomas19. [18F]Fluciclovine uptake reflects increased expression of amino acid transporters on CaP 
cell membranes20 with L-type amino acid transporter 1 expression associated with high Gleason Score 
(GS) aggressive CaP21.  
 
Half-body imaging performed at 3-5 minutes p.i ensures high tumour-background ratios and 
minimises tumoural washout of radiopharmaceutical. [18F]Fluciclovine has low urinary excretion, 
improving the ability to detect intraprostatic disease, although in 5-10% of cases, bladder activity may 
hinder assessment22. Elsewhere, there is intense physiological uptake in the liver and pancreas, 
moderate bone marrow uptake, moderate salivary and pituitary gland uptake, variable bowel uptake, 
and mild muscle activity, which increases with time22 (Figure 2). A standard administered activity of 
370 MBq results in an effective dose of 5.2 mSv23. 
 
Prostate Specific Membrane Antigen (PSMA) 
PSMA is a transmembrane glycoprotein, with intracellular, transmembrane and extracellular 
components. PSMA is expressed on endothelial cells within the neovasculature of both normal 
proliferative tissues24 and tumours including renal cell, transitional cell and colonic carcinomas25, 
whilst in the central nervous system, it is expressed on astrocytes and known as glutamate carboxylase 
II26. In the prostate, PSMA is expressed on the prostatic epithelium and in the majority of prostatic 
adenocarcinomas25,27,28, with PSMA expression greatest and most homogeneous in high grade 
tumours, heterogeneous and patchy in low-indeterminate grade tumours, and both significantly 
greater than in benign prostatic epithelium27,28. 
 
Initial PSMA imaging used the radiolabelled monoclonal antibody [111In]Capromab Pendetide 
(ProstaScint), to target the intracellular component of PSMA, which is only accessible through cell 
membrane destruction (necrosis or apoptosis), i.e. non-viable cells29. Images were hindered by poor 
tumour penetration and high background activity with resultant suboptimal detection of pelvic nodal 
disease in staging30. Consequently, PSMA PET radiopharmaceutical development focused on small 
urea based PSMA ligands (inhibitors), which target the extracellular active substrate recognition site 
of PSMA with high binding affinity, and are internalised and retained within CaP cells, thereby 
exhibiting rapid plasma clearance and high tumour-background ratios31.  
 
68Ga-labelled PSMA radiopharmaceuticals 
[68Ga]Ga-PSMA-11 or [68Ga]Ga-PSMA-HBED-CC, first described in 201232, is the most studied and 
utilised PSMA PET radiopharmaceutical. There is intense physiological uptake in the lacrimal and 
salivary glands, with slightly lower intensity uptake in the liver, spleen, bowel, and sympathetic 
ganglia, e.g. coeliac and cervical ganglia33, and minimal uptake in normal prostatic tissue and in bone 
marrow (Figure 3). [68Ga]Ga-PSMA-11 is predominantly renally excreted with intense activity in the 
urinary tract; focal ureteric activity can be mistaken for pathological nodal uptake or potentially 
obscure uptake in adjacent nodes, whilst bladder activity can hamper prostate bed assessment. 
 
Half body imaging is usually performed 60 minutes p.i34, although delayed time point imaging at 180 
minutes p.i increases uptake, contrast and DR, through clarification of equivocal lesions35,36. A 
modified protocol with imaging at 90 minutes p.i preceded by 1 litre pre-hydration and furosemide 
induced diuresis improves tumour contrast with the potential to increase DR37. A recommended 
injected activity between 1.8-2.2 MBq/kg up to a maximum of 200 MBq results in a maximum effective 
dose of 4.6 mSv38.  
 
[68Ga]Ga-PSMA-61739 and [68Ga]Ga-PSMA-I&T40 are alternative PSMA PET radiopharmaceuticals with 
similar imaging characteristics to [68Ga]Ga-PSMA-11 but with superior theranostic capabilities. At our 
institution, we use [68Ga]Ga-THP-PSMA, which offers rapid, room temperature, one-step kit based 
radiolabelling, similar to established techniques used for 99mTc-labelled radiopharmaceuticals41. It has 
lower physiological uptake in the salivary glands, liver, and spleen, in comparison with [68Ga]Ga-PSMA-
11 and [68Ga]Ga-PSMA-I&T, but with earlier renal excretion and higher urinary activity42,43; we 
routinely perform early dynamic pelvic imaging (0-10 minutes) to overcome this (Figure 4). Tracer 
uptake in malignant lesions, measured using maximum standardised uptake values (SUVmax), is 
significantly with lower with [68Ga]Ga-THP-PSMA compared with [68Ga]Ga-PSMA-11 (SUVmax 10.7 vs. 
SUVmax 30.3)42 and [68Ga]Ga-PSMA-I&T (SUVmax 7.5 vs SUVmax 21.3)43, but with similar tumour-
background ratios. A maximum administered activity of 200 MBq results in an effective dose of 4.1 
mSv.  
 
18F-labelled PSMA radiopharmaceuticals 
Despite the success of 68Ga-labelled PSMA radiopharmaceuticals, disadvantages include; 68Ge/68Ga 
generator purchase costs; limited number of doses per generator elution, requiring several 
productions per day and/or purchasing of additional generators to meet demand; and relatively short 
physical half-life of 68Ga (68 minutes), which invariably limits 68Ga-labelled PSMA PET-CT examinations 
to centres with 68Ge/68Ga generators44. Research has focused on developing cyclotron produced 18F-
labelled PSMA PET radiopharmaceuticals, to allow a greater number of examinations due to higher 
amounts of available radioactivity from a cyclotron, wider availability due to the longer physical half-
life of 18F, and improved spatial resolution and image quality, due to its lower positron energy and 
range. 
 
[18F]DCFBC, the first 18F-labelled PSMA PET radiopharmaceutical, was limited by high blood pool 
activity hindering assessment of the pelvic nodal basins45. A second generation 18F-labelled PSMA PET 
radiopharmaceutical, [18F]DCFPyL, demonstrated very low blood pool activity and markedly higher 
uptake in malignant lesions compared to [18F]DCFBC46. Delayed time point imaging at 120 minutes p.i 
increases tumoural uptake, which can result in more detected lesions and a change in TNM staging47. 
A maximum administered activity of 370 MBq results in an effective dose of 6.1 mSv46. 
 
[18F]PSMA-1007, a more recently developed 18F-labelled PSMA PET radiopharmaceutical structurally 
related to PSMA-617, includes a chelator capable of binding therapeutic radionuclides. Its 
biodistribution is similar to other PSMA PET radiopharmaceuticals except for its minimal urinary 
clearance, due to its predominant hepatobiliary excretion and renal retention (Figure 5), which is 
advantageous for assessment of the pelvis48. Delayed imaging at 120 minutes p.i shows a significant 
increase in tumoural uptake with very low urinary activity in the bladder that reduces with time49. An 




mpMRI is the imaging modality of choice for patients with clinically suspected localised CaP with good 
diagnostic accuracy for cancer detection and extracapsular extension using the Prostate Imaging 
Reporting and Data System (PIRADS)3. In biopsy naïve patients, foci of clinically significant disease 
(PIRADS ≥3) are targeted with percutaneous biopsies, a strategy superior to systematic non-targeted 
biopsies50, to obtain histological confirmation and help risk stratify patients using the GS, mpMRI 
findings and PSA level51. Assessment for extraprostatic disease is vital prior to embarking upon 
curative intent radical prostatectomy (RP) or radiotherapy (RT) with current guidelines52 
recommending abdomino-pelvic CT and BS in patients with intermediate and high-risk CaP; PET-CT is 
challenging this status quo. 
 
Radiolabelled choline analogues 
Radiolabelled choline PET/PET-CT is superior to conventional imaging for extraprostatic disease 
detection53 but has limited accuracy in differentiating between benign and malignant intraprostatic 
pathologies54. Prospective studies evaluating the use of FCH PET-CT in patients with intermediate and 
high-risk CaP, have reported suboptimal sensitivities (45-73.2%) but high specificities (87.6-96%) for 
nodal disease55,56; sensitivity is improved for nodes ≥ 5mm in diameter55 but false positive nodal 
uptake remains problematic56 (Figure 6). These studies reported unexpected findings of metastatic 
bone disease, some in patients without histological evidence of nodal disease, with Beheshti et al. 
reporting a 15% (19/130 patients) change from surgical to non-surgical management55. A meta-
analysis of 10 radiolabelled choline PET/PET-CT studies (441 patients) confirmed suboptimal pooled 
sensitivity (49%) but high specificity (95%) for nodal disease along with a higher sensitivity associated 




There is a paucity of literature regarding [18F]Fluciclovine PET-CT use in staging of CaP. Small 
prospective single centre studies have confirmed higher uptake in tumoural foci compared to normal 
prostate, but not dissimilar to uptake in benign prostatic hyperplasia (BPH), thereby limiting 
specificity58,59. In addition, Jambor et al.59 reported that only 1 out of 7 patients with proven 
metastatic nodal disease were identified on pre-operative imaging with undetected nodes ≤ 7mm in 
maximum dimension59. A multi-centre trial of 68 patients with CaP (42 patients awaiting RP) reported 
that none of the 7 RP patients with histologically proven nodal disease demonstrated [18F]Fluciclovine 
uptake with the largest node ≤ 5mm in maximum dimension60; this reflects a combination of 
insufficient tumour burden in nodes to generate a detectable PET signal coupled with limitations of 
PET spatial resolution. A meta-analysis confirmed a pooled sensitivity of 87% and specificity of 84% 
for primary tumour detection, and pooled sensitivity of 56% and specificity of 98% for nodal staging61 
(Figure 7). 
 
68Ga-labelled PSMA radiopharmaceuticals 
A handful of studies have confirmed the superiority of 68Ga-labelled PSMA PET-CT over conventional 
imaging CaP staging62. A recent small prospective study of 20 patients undergoing extended lymph 
node dissection prior to RT, reported a 68Ga-labelled PSMA PET-CT sensitivity of 39%  for loco-regional 
nodal disease, compared with 8% for conventional MRI/CT63, whilst a prospective study of 113 
patients confirmed significantly higher sensitivity (96.2% vs 73.1%) and accuracy (99.1 vs 84.1%) using 
68Ga-labelled PSMA PET-CT compared with BS for metastatic bone disease, particularly in relation to 
lytic and marrow metastases64 (Figure 8).  
 
Several studies have assessed the diagnostic performance of 68Ga-labelled PSMA PET-CT for nodal 
staging using histopathological validation. The largest series of 208 patients reported a per patient 
sensitivity for nodal disease of 38.2% (21/55 patients) and per node sensitivity of 24.4% (42/172 
nodes); the median diameter of malignant nodes was 4.8mm (range 0.2-40mm) with < 15% of 
histologically proven malignant nodes measuring < 5mm in maximum diameter identified pre-
operatively65. A recent literature review identified 2 prospective studies (63 patients) with per patient 
sensitivities of 64-100%, per node sensitivities of 50-58%, and high specificities of 90-95%, and 9 
retrospective studies (696 patients) with per patient sensitivities of 33-100%, per node sensitivities of 
24.4-96%, and high specificities of 80-100%66. Koschel et al. in their review identified 5 meta-analyses, 
each including between 4-6 eligible studies, with reported pooled sensitivities of 61-80% and pooled 
specificities of 95-99% for nodal disease67.  
 
Despite its moderate sensitivity, 68Ga-labelled PSMA PET-CT has been shown to have a significant 
impact on management, with a 21% change in management intent in a multi-centre prospective 
Australian study using [68Ga]Ga-PSMA-11 PET-CT68 and a 24% management change in a recent study 
from our institution using [68Ga]Ga-THP-PSMA PET-CT69 (Figure 9). Results are eagerly awaited from 
the recently completed ProPSMA study, an Australian multi-centre prospective randomised control 
trial involving 300 patients with newly diagnosed CaP, which compares 68Ga-labelled PSMA PET-CT 
with conventional imaging and BS. Results will provide robust evidence regarding the diagnostic 
accuracy of 68Ga-labelled PSMA PET-CT, its incremental benefit over conventional imaging and 
resultant clinical impact, as well as important cost and outcome data70. 
 
18F-labelled PSMA radiopharmaceuticals 
There is limited evidence regarding the use of 18F-labelled PSMA PET-CT in CaP staging. Initial studies 
using [18F]DCFBC PET-CT confirmed its ability to differentiate intraprostatic tumour from BPH and 
normal prostate tissue but with inferior sensitivity to mpMRI71,72; there are no data regarding its 
efficacy for nodal disease detection. A preliminary study of 10 patients undergoing [18F]PSMA 1007 
PET-CT, reported intense uptake in all primary tumours, and excellent sensitivity (94%) for nodal 
disease, with 18/19 histologically proven lymph node metastases detected pre-operatively with a 
median nodal diameter of 5mm (range 1-18mm)48 (Figure 10). The only available prospective single 
centre phase II study assessing [18F]DCFPyL PET-CT in 25 patients, reported that all patients 
demonstrated focal increased prostatic uptake, the sensitivity and specificity for nodal disease was 
71.4% and 89%, respectively with 50% of involved nodes < 3mm in size, and 3 patients (12%) had 
unsuspected distant nodal metastatic disease73.  
 
COMPARATIVE STUDIES WITH PSMA PET RADIOPHARMACEUTICALS IN PRIMARY STAGING 
There are few comparative studies between PET radiopharmaceuticals in staging of CaP. A 
retrospective subgroup analysis of 20 patients who underwent both [68Ga]Ga-PSMA-11 PET-CT and 
[11C]choline PET-CT, found concordance in prostatic tumoural uptake but a greater number of involved 
nodes and bone metastases with [68Ga]Ga-PSMA-1174. A prospective study between [18F]PSMA-1007 
PET-CT and [68Ga]Ga-PSMA-11 PET-CT in 16 patients showed comparable ability to detect the 
dominant prostatic tumoural focus, although the absence of histologically proven nodal disease 
prevented further comparisons. A comparative study between [18F]PSMA-1007 PET-CT and 





Following RP or RT, 27-53% of patients develop BCR, which is defined as a rising PSA without 
corroborative histological or imaging evidence of disease relapse52; the PSA level that defines BCR 
depends on the primary treatment. Post-RP, after which PSA levels should reach undetectable levels 
within 4 weeks, a PSA level of ≥ 0.4 ng/ml, followed by further increase, is the best predictor of 
metastatic disease progression, although 2 or more successive PSA rises ≥ 0.2 ng/ml is an acceptable 
alternative definition76. Following RT, the definition of treatment failure, is any PSA increase ≥ 2.0 
ng/ml higher than the PSA nadir value, regardless of the nadir value77.  
 
BCR does not indicate inevitable progression to clinically significant disease and/or CaP related 
mortality. In a cohort of nearly 2000 post-RP patients, 304 (15%) patients developed BCR, with only 
103 of those patients (34%) developing metastatic disease within the 15-year follow-up period, with 
a median of 8 years from BCR to the development of detectable metastatic disease78. Despite this, 
with appropriate risk stratification and identification of high-risk features79, early salvage treatment, 
in particular salvage RT at low PSA levels can improve outcome80. 
 
Radiolabelled choline analogues 
Radiolabelled choline PET/PET-CT is superior to conventional imaging in BCR81,82 with several meta-
analyses confirming high diagnostic accuracy83-85; a meta-analysis of [11C]choline PET/PET-CT studies 
reported an overall DR of 62% with pooled sensitivity and specificity of 89% for any site relapse83 
(Figure 11). The DR and sensitivity of radiolabelled choline PET-CT is dependent on PSA level and PSA 
kinetics, i.e. PSA doubling time (PSAdt) and PSA velocity (PSAvel)86. A systematic review of the role of 
imaging in early recurrent CaP reported pooled DRs for [11C]choline PET/PET-CT of 0-31.3% at PSA 
levels < 0.5 ng/ml, and 14.3-44.1% at PSA levels < 1.0 ng/ml, which were slightly better with FCH/FEC 
PET/PET-CT (8.3-28.1% PSA < 0.5 ng/ml, 16.7-76.0% PSA < 1.0 ng/ml)87. A meta-analysis of 
radiolabelled choline PET-CT studies reported a pooled DR of 58% with a significant rise in DR to 65% 
if the PSAdt was ≤ 6 months, and up to 71% and 77% if the PSAvel was > 1.0 or > 2.0 ng/ml/year, 
respectively88.  
 
This superiority of radiolabelled choline PET/PET-CT over conventional imaging in BCR translates into 
changes in clinical management. A prospective multi-centre trial assessing the impact of FCH PET-CT 
in 179 patients with prior negative/equivocal conventional imaging, reported a 56% change in 
management89. A 150 patient retrospective study assessing the impact of [11C]choline PET-CT 
reported a slightly lower overall clinical impact of 46.7% (70/150 patients), with 38.6% (27/70) of 
decisions classed as a major change in management (switch from salvage to palliative therapy or vice 
versa) and 61.4% (43/70) as minor (same therapeutic category but with adjustment)90 (Figure 12). 
Although incorporated into early iterations of international CaP guidelines52, radiolabelled choline 
PET-CT in BCR is being replaced by more novel PET radiopharmaceuticals, as discussed later. 
 
[18F]Fluciclovine 
[18F]Fluciclovine PET-CT is superior to ProstaScint single photon emission computed tomography 
(SPECT)-CT91, contrast-enhanced CT92 and [11C]choline PET-CT93 in BCR with meta-analyses confirming 
pooled sensitivities of 79-87% and specificities of 66-69%61,94, although DRs at different PSA levels are 
not reported. Higher DRs at higher PSA levels have been observed in smaller studies and confirmed in 
larger prospective trials (Figure 13). The multicentre retrospective BED-001 study of 596 patients95, 
reported an overall DR of 67.7% (median PSA 2.0 ng/ml, range 0.05-82.0 ng/ml) and a 41% DR at a 
PSA level ≤ 0.79 ng/ml. The US multi-centre prospective LOCATE study of 213 patients reported an 
overall DR of 57% (median PSA 1.0 ng/ml, range 0.2-93.5 ng/ml), DRs of 31%, 50%, 66% and 84% at 
PSA levels of < 0.5 ng/ml, 0.5-1.0 ng/ml, 1.0-2.0 ng/ml, and > 2.0 ng/ml, respectively, and was 
associated with a 59% (126/213 patients) change in management, of which 78% (98/126) were 
‘major’, i.e. change in treatment modality96. The smaller UK multi-centre prospective FALCON study 
of 104 patients, reported an overall DR of 56% (median PSA 0.79 ng/ml, range 0.04-28.0 ng/ml), DRs 
of 33% and 93% at PSA levels of ≤ 1.0 ng/ml, and > 2.0 ng/ml, respectively, and an was associated with 
a 63% change in management (66/104) of which 65% (43/66) of decisions were major97. 
[18F]Fluciclovine was approved by the U.S Food and Drug Administration (FDA) for recurrence 
detection in CaP in May 2016, received marketing authorisation by the European Medicines Agency 
(EMA) in May 2017, and is pending approval by the National Institute for Health Care and Excellence 
(NICE). 
 
68Ga-labelled PSMA radiopharmaceuticals 
68Ga-labelled PSMA PET-CT is superior to conventional imaging98-100 and other available PET 
radiopharmaceuticals in BCR, particularly at low PSA levels with DRs between 11.3-58.3% at PSA levels 
< 0.2 ng/ml, and 11.0-65.0% at PSA levels < 0.5 ng/ml87. Perera et al.101 in a 2019 meta-analysis 
reported impressive pooled DRs at low PSA levels (33% PSA < 0.2 ng/ml, 45% PSA 0.2-0.5 ng/ml), 
similar to results by Hope et al., which only incorporated studies with histological validation, with 
pooled sensitivity of 99%, specificity of 76% and a 40% DR at a PSA < 0.2 ng/ml102. Although a recent 
meta-analysis demonstrated an increase DR with shorter doubling times (60% PSAdt > 6 months, 83% 
in patients with a PSAdt < 6 months)103, this was not statistically significant and there remains no clear 
correlation between PSA kinetics and 68Ga-labelled PSMA PET-CT DR in BCR. 
 
Large prospective trials published since these meta-analyses have shown similar results. A multi-
centre prospective trial of 635 patients reported an overall DR of 75% (median PSA 2.1 ng/ml, range 
0.1-1154 ng/ml), which increased with PSA level (38% PSA < 0.5 ng/ml, 57% PSA 0.5-1.0 ng/ml, 84% 
PSA 1.0-2.0 ng/ml)104, whilst a single centre prospective trial of 314 patients reported an overall DR of 
62.7% (median PSA 0.83 ng/ml, range 0.003-80 ng/ml), which also increased with PSA level (27.3% 
PSA < 0.2ng/ml, 47.1% PSA 0.2-1.0 ng/l, 75% PSA 1.0-2.0 ng/ml)105; both studies failed to demonstrate 
a significant correlation between DR and PSAdt.  
 
High DRs at such low PSA levels result in significant changes in management. A review of 12 68Ga-
labelled PSMA PET-CT studies (1346 patients) reported management change ranging between 30.2-
76.0%106; amongst 60% of patients, the main changes were avoidance of systemic therapy and new 
indication for PET-directed therapy, which included prostate/pelvic bed RT or treatment of 
oligometastatic disease (Figure 14). 
 
The majority of evidence for 68Ga-labelled PSMA PET-CT in BCR revolves around [68Ga]Ga-PSMA-11, 
but other 68Ga-labelled PSMA ligands including [68Ga]Ga-PSMA-IT&T107 and [68Ga]Ga-THP-PSMA69,108 
have been assessed. A retrospective analysis of 99 patients post-RP undergoing [68Ga]Ga-THP-PSMA 
PET-CT reported an overall DR of 52.5% (mean PSA 94.1 ng/ml, range 0.01-8400 ng/ml), with DRs of 
22.2%, 20%, 14.3% and 54.5% at PSA levels of < 0.2 ng/ml, 0.2-0.5 ng/ml, 0.5-1.0 ng/ml and 1.0-2.0 
ng/ml, which are lower than with other PSMA PET radiopharmaceuticals108. Despite this, a recent 
study of 68 patients with BCR from our institution confirmed the clinical impact of [68Ga]Ga-THP-PSMA 
PET-CT with a 34% (23/68) change in management with a similar overall DR of 59% (mean PSA 4.4 
ng/ml, range 0.16-71.02 ng/ml)69 (Figure 15). 
 
18F-labelled PSMA radiopharmaceuticals 
Although the evidence base for 18F-labelled PSMA PET-CT in BCR is relatively immature, a systematic 
review and meta-analysis of 6 studies (645 patients) reported an overall pooled DR of 81% and 49% 
DR at PSA levels ≤ 0.5 ng/ml109. A prospective study assessing [18F]DCFBC PET-CT in 68 patients 
reported an overall DR of 60.3% (mean PSA 4.4 ng/ml, range 0.2-37.4 ng/ml), which increased with 
PSA level (15% PSA < 0.5 ng/ml, 46% PSA 0.5-1.0 ng/l, 83% PSA 1.0-2.0 ng/ml) and was associated with 
a 51.2% management change, despite its known limitation of high blood pool activity110.  
 
A prospective study assessing [18F]DCFPyL PET-CT in 130 patients111, reported a higher overall DR of 
84.6% (mean PSA 5.2 g/ml), higher DRs at low PSA levels (60% PSA 0.4-0.5 ng/ml, 78% PSA 0.5-1.0 
ng/ml) and higher change in management (87.3%) compared to [18F]DCFBC PET-CT110. A further 
prospective study assessing [18F]DCFPyL PET-CT in 90 patients reported an overall DR of 77.8% (median 
PSA 2.5ng/ml, range 0.21-35.5 ng/ml) and broadly similar PSA specific DRs but found that in post-
prostatectomy patients exclusively, PSA level, PSAdt and PSAvel correlated with PET-CT DRs112.  
 
A prospective study assessing [18F]PSMA-1007 PET-CT in 40 patients with BCR with PSA levels ≤ 2.0 
ng/ml reported an overall DR of 60% (median PSA 0.65 ng/ml), which was dependent on PSA level 
(39% PSA < 0.5 ng/ml, 55% PSA 0.5-1.0 ng/ml, 100% PSA 1.0-2.0 ng/ml)113, whilst a larger retrospective 
analysis of 251 patients reported a higher overall DR of 81.3% (median PSA 1.2ng/ml, range 0.2-228 
ng/ml) with DRs of 61.5%, 74.5%, 90.9% at PSA levels of 0.2-0.5 ng/ml, 0.5-1.0 ng/ml, 1.0-2.0 ng/ml114, 
respectively; these are comparable, if not better than those published for other PSMA PET 
radiopharmaceuticals (Figure 16). 
 
COMPARATIVE STUDIES WITH PSMA PET RADIOPHARMACEUTICALS IN BCR 
68Ga- and 18F-labelled PSMA vs. radiolabelled choline 
A prospective comparative study between [68Ga]Ga-PSMA-11 PET-CT and FCH PET-CT in 38 patients 
reported a superior overall DR for [68Ga]Ga-PSMA-11 compared to FCH (66% vs. 32%) across all PSA 
levels (mean 1.72 ng/ml, range 0.04-12.0 ng/ml) and most evident at low PSA levels, e.g. 50% vs. 12.5% 
PSA < 0.5 ng/ml115. A similar sized prospective study comparing [68Ga]Ga-PSMA-11 PET-CT and 
[11C]choline PET-CT reported similar findings116. The only available prospective head-to-head 
comparison of [18F]PSMA-1007 PET-CT and FCH PET-CT in 40 patients with BCR and PSA levels ≤ 2.0 
ng/ml (median PSA 0.7 ng/ml), confirmed the superiority of [18F]PSMA-1007 with a significantly higher 
DR and higher number of lesions detected per patient117. A meta-analysis of 5 head-to-head 
comparison studies between PSMA PET-CT and radiolabelled choline PET-CT, reported a higher overall 
DR (78% vs. 56%) and higher DR at PSA levels ≤ 1.0ng/ml (54% vs. 27%) for PSMA PET-CT118. 
 
68Ga- and 18F-labelled PSMA vs. [18F]Fluciclovine 
Calais et al. conducted a robustly designed prospective head-to-head comparison study between 
[68Ga]Ga-PSMA-11 PET-CT and [18F]Fluciclovine PET-CT in 50 patients (PSA ≤ 2.0 ng/ml) post-RP; 44/50 
patients (88%) had a PSA level ≤ 1.0ng/ml119. Overall DRs were significantly higher with [68Ga]Ga-
PSMA-11 (56% vs. 26%) at all PSA levels (46% vs. 27% PSA 0.2-0.5 ng/ml, 67% vs. 28% PSA 0.5-1.0 
ng/ml, 67% vs. 17% PSA 1.0-2.0 ng/ml), with tumour-background ratios for PET positive lesions 7 times 
higher with [68Ga]Ga-PSMA-11 than with [18F]Fluciclovine. Although DRs for prostate bed recurrence 
were similar, for sites of extraprostatic disease (nodal, skeletal and visceral), DRs were > 2 times higher 
with [68Ga]Ga-PSMA-11. A similar sized prospective comparative study between [68Ga]Ga-PSMA-11 
PET-CT and [18F]Fluciclovine PET-CT in 58 patients (post-RP or post-RT), reported no significant 
difference in overall DRs (82.8% vs. 79.3%). However, comparative DRs at clinically important low PSA 
levels, i.e. ≤ 2ng/ml were not reported, which is relevant given the heterogeneous patient cohort 
assessed and their widely varying PSA levels (median PSA 14.9 ng/ml, range 0.2-230 ng/ml) at the time 
of imaging120. 
 
68Ga-labelled PSMA vs. 18F-labelled PSMA 
A retrospective study of 191 patients who underwent either [18F]DCFPyL PET-CT or [68Ga]Ga-PSMA-11 
PET-CT with 25 patients undergoing sequential examination with both radiopharmaceuticals121, 
reported  that at PSA levels between 0.5-3.5 ng/ml, DRs were higher with [18F]DCFPyL, whilst in the 25 
patients examined with both radiopharmaceuticals, [18F]DCFPyL detected additional lesions in all 
positive [68Ga]Ga-PSMA-11 PET-CT scans.  
 
A retrospective analysis of [18F]PSMA-1007 PET-CT findings in a cohort of 102 patients post-RP (median 
PSA 0.87 ng/ml, range 0.2-13.6 ng/ml), which were compared with a clinically matched cohort of 
different patients, who underwent [68Ga]Ga-PSMA-11 PET-CT (median PSA 0.91 ng/ml, range 0.18-
30.0 ng/ml), reported a similar number of PSMA-avid lesions attributable to recurrent disease with 
both radiopharmaceuticals and identical overall per patient DRs of 80.4%122. However, [18F]PSMA-
1007 revealed almost 5 times more benign PSMA avid foci compared to [68Ga]PSMA-11, mainly in 
ganglia, unspecified lymph nodes and bone lesions, the latter of which were mainly in the ribs as well 
as vertebral column and pelvis, and importantly, without CT correlate. An intra-individual comparison 
of [18F]PSMA-1007 PET-CT with other PSMA radiopharmaceuticals in 27 patients, showed an improved 
confidence to interpret small loco-regional nodes adjacent to the urinary tract with [18F]PSMA-1007 
PET-CT due to its low urinary excretion123 (Figure 17). However, similar to the Rauscher et al.122, a 
high number of non-specific unrelated PSMA-avid marrow foci were demonstrated, which were 
without CT correlate or signal abnormality on subsequent contrast-enhanced MRI evaluation. Both 
these studies emphasise the need for sophisticated reader training in [18F]PSMA-1007 PET-CT and the 
importance of considering the clinical context when reporting such studies. 
 
CONCLUSION 
PET-CT in CaP is superior to conventional imaging (CT and BS) both for staging and in BCR due to their 
high DRs at clinically relevant low PSA levels, with resultant significant impact on patient management. 
Novel PET radiopharmaceuticals continue to be developed124 including [18F]PSMA-11125, [18F]JK-
PSMA-7126, and most recently radiohybrid PSMA (rhPSMA) ligands, which are a new class of 
theranostic PSMA-targeting PET agent, which have shown promising initial data in the setting of BCR 
post-RP127. 
 
Despite the growing body of evidence demonstrating the superiority of 68Ga- and 18F-labelled PSMA 
PET radiopharmaceuticals, they remain without FDA, EMA or NICE approval. Nevertheless, PSMA PET-
CT has been incorporated into the most recent iteration of the joint EAU-ESTRO-ESUR-SIOG guidelines 
on CaP52, and is currently recommended for use in patients with persistent or newly raised PSA levels 
(> 0.2 ng/ml) post-RP, or in patients with PSA recurrence post-RT who are eligible for curative salvage 
surgery. PSMA PET-CT in staging is currently not recommended due to uncertainty regarding the 
clinical benefit of detecting extraprostatic sites of disease at such an early timepoint, and the optimal 
management of such patients, e.g. systemic therapy vs. primary tumour directed treatment in 
conjunction with metastasis-directed therapy. Randomised prospective clinical trials including the 
recently completed ProPSMA study70, comparing management based on conventional imaging/non-
PSMA PET-based radiopharmaceutical imaging vs. PSMA PET-CT guided treatment, for both staging 
and BCR, are required to provide information on comparative diagnostic accuracy, impact on 
management, and most importantly clinical outcomes. The emergence of such data will help establish 
PSMA PET-CT into routine clinical practice. 
  
FIGURE LEGENDS 
Figure 1: Normal biodistribution of FEC. 
Physiological biodistribution of FEC on PET maximum intensity projection (MIP) (A) and sagittal PET 
(B). Note symmetrical low-grade uptake frequently demonstrated in small reactive intrathoracic 
nodes (solid back and white arrows) on coronal PET and fused PET-CT images (C&D). 
 
Figure 2: Normal biodistribution of [18F]Fluciclovine. 
Physiological biodistribution of [18F]Fluciclovine on PET MIP (A) and sagittal PET (B). Note the minimal 
urinary activity in the bladder (*) on axial PET and fused PET-CT images (C&D). Images courtesy of Dr 
Eugene Teoh, Blue Earth Diagnostics Ltd, Oxford, UK. 
 
Figure 3: Normal biodistribution of [68Ga]GaPSMA-11. 
Physiological biodistribution of [68Ga]Ga-PSMA-11 on PET MIP (A) and sagittal PET (B). Note low-grade 
uptake in the left cervical ganglion (dashed white arrows) and left coeliac ganglion (solid white arrows) 
on axial PET and fused PET-CT images (C&D and E&F), not to be misinterpreted as pathological nodal 
uptake. 
 
Figure 4: Normal biodistribution of [68Ga]Ga-THP-PSMA. 
Physiological biodistribution of [68Ga]Ga-THP-PSMA on PET MIP (A) and sagittal PET (B) with the 
intensity of physiological uptake, including prominent duodenal uptake, lower than that observed 
with [68Ga]Ga-PSMA-11. Early dynamic axial CT and fused PET-CT images at 0-3 minutes (C&D), 3-7 
minutes (E&F) and 7-10 minutes (G&H) enable assessment of the prostate bed prior to accumulation 




Figure 5: Normal biodistribution of [18F]PSMA-1007. 
Physiological biodistribution of [18F]PSMA-1007 on PET MIP (A) and sagittal PET (B) in a similar 
biodistribution to [68Ga]Ga-PSMA-11. Note the minimal urinary activity in the bladder (*) on axial CT 
and fused PET-CT images (C&D) and focal uptake in a left sacral ganglion (white arrowheads), coeliac 
ganglia (dashed white arrows) and cervical ganglia (solid white arrows) on axial CT and fused PET-CT 
images (E&F, G&H and I&J). Images courtesy of GenesisCare, Oxford, UK. 
 
Figure 6: FEC PET-CT in staging of CaP. 
GS 4 + 3 CaP, PSA 9.3ng/ml, T2aN0 on mpMRI. PET MIP (A) axial CT, PET and fused PET-CT images (B-
D) demonstrate a choline avid (SUVmax 6.3) right basal prostatic tumour (*). Axial CT, PET and fused 
PET-CT images (E-G) demonstrate low-grade uptake (SUVmax 2.3) in non-enlarged right obturator and 
right internal iliac nodes (solid black and white arrows) and a similar sized, similar avidity (SUVmax 
2.5) left obturator node (dashed black and white arrow); the right pelvic nodes were metastatic on 
histology, but there was no metastatic disease in the resected left pelvic nodes. 
 
Figure 7: [18F]Fluciclovine PET-CT in staging of CaP. 
GS 4 + 5 CaP, PSA of 32ng/ml. PET MIP (A), axial CT and axial fused PET-CT images (B&C, D&E) 
demonstrate fluciclovine uptake in 2 sub-cm short axis diameter right internal and external iliac nodes 
(black and white solid arrows) and a similar sized, similar avidity left internal iliac node (black and 
white dashed arrows); these were confirmed metastatic on histology. Note the minimal urinary 
activity in the bladder (*) with [18F]Fluciclovine. Images courtesy of Professor David Schuster, Emory 
University, USA. 
 
Figure 8: [68Ga]Ga-PSMA-11 PET-CT in staging of CaP. 
GS 4 + 3 CaP, PSA 300 ng/ml, T3aN0M0 on mpMRI. Negative BS. PET MIP (A), axial CT and fused PET-
CT images (B&C, D&E, F&G) demonstrate an intensely PSMA avid (SUVmax 37.1) bilateral prostatic 
tumour (*) with a tiny PSMA avid (SUVmax 5.4) right internal iliac node (solid white arrow) and a small 
left femoral marrow metastasis (dashed white arrow). 
 
Figure 9: [68Ga]Ga-THP-PSMA PET-CT in staging of CaP. 
GS 4 + 4 CaP, PSA 27.7ng/ml, T3bN0M0 on mpMRI. Negative BS. PET MIP (A), axial CT and fused PET-
CT images (B&C) demonstrate high-grade uptake (SUVmax 12.5) in a predominantly left sided 
prostatic tumour (*) with low-grade uptake (SUVmax 1.6) in a 6 x 6mm left internal iliac node (black 
and white dashed arrows) on axial PET and fused PET-CT images (D&E), high-grade uptake (SUVmax 
11.1) in a 14 x 14mm superior mesorectal node (solid black and white arrows) and a L2 vertebral body 
metastasis (black and white arrowheads) on axial CT and fused PET-CT images (F&G, H&I).  
 
Figure 10: [18F]PSMA-1007 PET-CT in staging of CaP. 
GS 4 + 4 CaP, PSA 20 ng/ml, T3bN0M0 on mpMRI. Intensely PSMA avid (SUVmax 16.0) bilateral 
peripheral zone prostatic tumour (*) on PET MIP (A) and axial CT and fused PET-CT images (B&C) 
concordant with mpMRI sequences; axial T2-weighted (D), DCE-MR (E), DW (F) and apparent diffusion 
coefficient (G) imaging. Note symmetrical low-grade uptake in bilateral non-enlarged distal external 
iliac nodes presumed benign and reactive (solid black and white arrows) and heterogeneous rib 
uptake, e.g. right 2nd rib (dashed black and white arrows) without CT abnormality, on PET MIP (A), axial 
CT and fused PET-CT images (H&I, J&K), also presumed benign122,123. Images courtesy of GenesisCare, 
Oxford, UK. 
 
Figure 11: [11C]choline PET-CT in BCR. 
GS 3 + 4 CaP, post-RP with left pelvic nodal dissection (pT3aN1M0) with PSA rise to 5.4ng/ml. PET MIP 
(A), axial CT and fused PET-CT images (B&C, D&E) demonstrate 2 choline avid left internal iliac nodes 
(solid black and white arrows) measuring 10 x 13mm (SUVmax 8.3) and 8 x 11mm (SUVmax 7.1). Note 
the minimal urinary activity in the bladder (*). 
Figure 12: FEC PET-CT in BCR. 
GS 4 + 5 CaP, post-RP and bilateral pelvic nodal dissection (pT3bN1M0) with positive resection margins 
and rapid PSA rise to 15ng/ml; staging CT only identified an old ‘traumatic’ fracture of the right pubic 
ramus. PET MIP (A), axial CT and fused PET-CT images (B&C, D&E, F&G, H&I) demonstrate multi-focal 
sites of choline avid recurrent disease including sclerotic right inferior pubic ramus (*) and CT occult 
left inferior pubic ramus (black and white arrowheads) bone metastases, and left hilar (solid black and 
white arrows) and left supraclavicular fossa nodal metastases (dashed black and white arrows). 
 
Figure 13: [18F]Fluciclovine PET-CT in BCR. 
T3aN0M0 CaP, post-RT with rising PSA. PET MIP (A), axial CT and fused PET-CT images (B&C, D&E) 
demonstrate multiple, predominantly non-enlarged sub-cm short axis diameter retroperitoneal nodes 
(solid and dashed black and white arrows). Note the minimal urinary activity in the bladder (*). Images 
courtesy of Dr Eugene Teoh, Blue Earth Diagnostics Ltd, Oxford, UK. 
 
Figure 14: [68Ga]Ga-PSMA-11 PET-CT in BCR 
GS 3 + 4 CaP, post-RP (pT2N0M0) with PSA rise to 3.7ng/ml. PET MIP (A), axial CT and fused PET-CT 
images (B&C, D&E) demonstrate an intensely PSMA avid (SUVmax 26.4) 4 x 6mm external iliac node 
(dashed black and white arrows) and moderately PSMA avid (SUVmax 7.3) 4 x 6mm left common iliac 
node (solid black and white arrows). 
 
Figure 15: [68Ga]Ga-THP-PSMA PET-CT in BCR. 
GS 4 + 3 CaP, post-RP and left pelvic lymph node dissection (pT3bN1M0) with PSA rise to 1.4ng/ml. 
PET MIP (A), axial CT and fused PET-CT images (B&C, D&E) demonstrate low-grade PSMA uptake 
(SUVmax 4.1) in a 8 x 9mm left para-aortic node (dashed white arrows) and a similar sized, similar 
intensity aortocaval node (solid black and white arrows) in keeping with disease relapse. 
 
Figure 16: [18F]PSMA-1007 in BCR. 
GS 4 + 5 CaP, post-RP with nodal dissection (pT3bN1M0) with PSA rise to 0.98ng/ml. PET MIP (A), axial 
CT and fused PET-CT images (B&C, D&E, F&G) demonstrate an intensely PSMA avid (SUVmax 63.4) 12 
x 14mm nodule (black and white arrowheads) anterior to the bladder containing minimal urinary 
activity (*) and a PSMA avid (SUVmax 26.2) solitary sclerotic right iliac bone metastasis (solid black 
and white arrows). Note incidental PSMA avid (SUVmax 8.4) T5 vertebral Paget’s disease (dashed 
white arrows) with heterogeneous sclerosis, cortical thickening and expansion on CT. Images courtesy 
of GenesisCare, Oxford, UK. 
 
Figure 17: [18F]PSMA-1007 in BCR 
GS 4 + 3 CaP, post-RP with PSA rise to 4ng/ml. PET MIP (A), axial CT and fused PET-CT images (B&C, 
D&E) demonstrate PSMA avid local recurrence in the right prostatectomy bed (black and white 
arrowheads) not appreciable on CT, and only discernible on PET, due to the absence of significant 
urinary activity in the bladder. Axial CT and fused PET-CT images (F&G, H&I) demonstrate a 5 x 6mm 
PSMA avid (SUVmax 5.0) right obturator node (black and white dashed arrows) and a PSMA avid 5 x 
7mm (SUVmax 8.3) right external iliac node (solid black and white arrows). Note the equivocal left iliac 
bone focus (*) without CT abnormality. Images courtesy of GenesisCare, Oxford, UK. 
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